|Articles|February 1, 2009
Triple therapy AMD trial to continue
The Phase II RADICAL study (Reduced Fluence Visudyne Anti-VEGF-Dexamethasone In Combination for AMD Lesions) is to continue as planned, following promising interim results and the positive recommendations of the independent Data and Safety Monitoring Committee.
Advertisement
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times Europe
1
Beyond anti-VEGF: The next wave in retinal therapy
2
Demodex blepharitis: Closing the diagnostic gap to improve ocular surface health
3
Trehalose-hyaluronate combination aids tear film after eyelid surgery
4
ZEISS reports early implantations of AT LUCIA Toric 721P IOL in Europe
5
















